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http://www.biomedcentral.com/1471-2253/12/25RESEARCH ARTICLE Open AccessHigh-sensitive cardiac Troponin T is superior to
echocardiography in predicting 1-year mortality
in patients with SIRS and shock in intensive care
Lill Bergenzaun1*, Hans Öhlin2, Petri Gudmundsson3, Joachim Düring4, Ronnie Willenheimer5
and Michelle S Chew6Abstract
Background: Left ventricular (LV) dysfunction is well documented in the critically ill. We assessed 1-year mortality in
relation to cardiac biomarkers and LV function parameters by echocardiography in patients with shock.
Methods: A prospective, observational, cohort study of 49 patients. B-natriuretic peptide (BNP), high-sensitive
troponin T (hsTNT) and transthoracic echocardiography (TTE) were assessed within 12 h of study inclusion. LV
systolic function was measured by ejection fraction (LVEF), mean atrioventricular plane displacement (AVPDm), peak
systolic tissue Doppler velocity imaging (TDIs) and velocity time integral in the LV outflow tract (LVOT VTI). LV
diastolic function was evaluated by transmitral pulsed Doppler (E, A, E/A, E-deceleration time), tissue Doppler
indices (é, á, E/é) and left atrial volume (La volume). APACHE II (Acute Physiology and Chronic Health Evaluation)
and SOFA (Sequential Organ Failure Assessment) scores were calculated.
Results: hsTNT was significantly higher in non-survivors than in survivors (60 [17.0-99.5] vs 168 [89.8-358] ng/l,
p = 0.003). Other univariate predictors of mortality were APACHE II (p = 0.009), E/é (p = 0.023), SOFA (p = 0.024) and
age (p = 0.031). Survivors and non-survivors did not differ regarding BNP (p = 0.26) or any LV systolic function
parameter (LVEF p = 0.87, AVPDm p= 0.087, TDIs p = 0.93, LVOT VTI p = 0.18). Multivariable logistic regression
analysis identified hsTNT (p = 0.010) as the only independent predictor of 1-year mortality; adjusted odds ratio
2.0 (95% CI 1.2- 3.5).
Conclusions: hsTNT was the only independent predictor of 1-year mortality in patients with shock. Neither BNP nor
echocardiographic parameters had an independent prognostic value. Further studies are needed to establish the
clinical significance of elevated hsTNT in patients in shock.
Keywords: Echocardiography, BNP, High-sensitive TNT, Myocardial function, Mortality, ShockBackground
Myocardial depression is a well-known complication of
septic shock [1,2]. Raised levels of cardiac biomarkers
such as natriuretic peptides [3,4] and cardiac troponin
(cTn) [5], as well as echocardiographic changes of LV
function [6-8] are frequently described. cTn is highly
useful for both diagnosis and prognostication in patients
with cardiac disease [5,9]. The recent introduction of a* Correspondence: lill.bergenzaun@skane.se
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distribution, and reproduction in any mediumnew generation of high sensitivity assays for cTn with
lower cut-off values suggests advantages over traditional
cTn in terms of accuracy [10], diagnosis [11] and prog-
nostication [11,12] in patients with cardiac disease as
well as in the general population [13]. In intensive care
patients elevated cTN is related to mortality [14-16] and
one study showed that hsTNT correlated to the severity
of disease and was significantly higher in hospital non-
survivors compared to survivors [17].
Elevated levels of natriuretic peptides such as
B-natriuretic peptide (BNP) and amino- terminal frag-
ment of BNP (NT-proBNP) are known to be strong prog-
nostic markers in patients with cardiovascular diseasentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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proBNP can be found in many patients for a variety of
reasons [20] and can be used as prognostic indicators
[21,22]. Echocardiography is regarded useful for assessing
cardiac function [23] but there are conflicting data
regarding the prognostic value of LV systolic and dia-
stolic function in patients in the intensive care unit
(ICU) [3,4,24,25]. We investigated well established para-
meters of LV systolic [26-29] and diastolic function [30],
where the latter have gained interest in ICU populations
during the recent years [3,25].
The aim of this study was to investigate whether
hsTNT, BNP and echocardiographic parameters of LV
function measured within 12 h are associated with 1-
year mortality in patients with shock.
Methods
The study was approved by the Regional Ethics Review
Board, Lund, Sweden (Dnr.187/2005). Informed consent
was sought from the patient or, if not possible, from the
next of kin. The study design was a prospective observa-
tional cohort study. Patients >18 years old admitted to the
mixed-bed ICU of Skåne University Hospital, Malmö,
Sweden, were screened for eligibility. We included 55 con-
secutive patients with Systemic Inflammatory Response
Syndrome (SIRS) and shock, defined as failure to maintain
mean arterial pressure≥ 70 mmHg, despite adequate
fluid resuscitation according to the surviving sepsis cam-
paign algorithm [31]. Exclusion criteria were pregnancy,
pre-existing abnormalities of coagulation, fibrinolytic
therapy, compromised immunity or a “Do Not Attempt
Resuscitation” order. Patients could only be included
once. This study was part of a larger project over a
7 day period investigating other aspects of critical illness
[32] independent of our study aim. APACHE II scores
[33] were calculated at admission and SOFA scores [34]
were calculated after 24 h. After the initial resuscitation
period, fluids were given at the treating clinician’s
discretion.
Biochemical analyses
Blood samples were taken from an indwelling arterial line
within 12 h of inclusion. They were sent to the local
clinical chemistry laboratory, Skåne University Hospital,
Malmö, Sweden, where they were centrifuged, frozen
at −80°C and stored. hsTNT was measured using
immunoassay (Cobas e601, Roche Diagnostics GmbH,
Penzberg, Germany) [10]. The measuring range is 3–10
000 ng/L and the upper reference limit (99th percentile) is
14 ng/l in healthy volunteers. The inter-assay coefficient
of variation (CV) was <10%. Plasma BNP levels were
analysed using UniCelTM DxI 800 Beckman Access W Im-
munoassay System (Beckman-Coulter Chaska, Brea, U.S.A.).
The measuring range is 0.29- 1445 pmol/l and the upperreference limit is 30 pmol/l. The inter-assay CV was
<10%. Biochemical samples were coded before analysis
and laboratory personnel were blinded to clinical and
echocardiographic data.
Transthoracic echocardiography (TTE)
TTE examinations were performed within 12 h hours of
inclusion by either of four experienced echocardiogra-
phers (LB, MC, PG, MD). Images were acquired using a
Hewlett- Packard Sonos 5500 (Andover, Mass, U.S.A)
scanner and a 3 MHz transducer. Two-dimensional (2D)
imaging examinations were performed in the standard
apical four- and two- chamber views (2C- and 4C views).
Tissue harmonic imaging was used to enhance 2D image
quality. Parameters of LV systolic function (LV ejection
fraction [LVEF], mean atrioventricular plane displace-
ment [AVPDm], peak systolic tissue Doppler velocity
imaging [TDIs] and velocity time integral in the LV out-
flow tract [LVOT VTI]) were acquired as described pre-
viously [35]. Transmitral velocities were measured with
pulsed-wave Doppler (PW) in the 4C view. For LV dia-
stolic function, we used La volume and from the mitral
inflow profile, the E- and A- velocity and E-deceleration
time was measured. PW tissue Doppler recorded
the diastolic velocities (é, á) of the LV septal wall at the
level of the mitral annulus in the apical 4C view [36].
The E/A ratio as well as the E/é ratio, an index of LV
filling pressure, were calculated [30]. La volume was esti-
mated in the 4C view [37] and indexed to body surface
area [30]. All TTE studies were recorded over three con-
secutive cardiac cycles independently of the respiratory
cycle and averaged. In patients with non-sinus rhythm
measurements were collected over 5–10 heartbeats.
Analyses of the measurements were made >16 weeks
after the data acquisition when the reader was less
aware of the diagnosis in Phillip’s digital storing pro-
gram Xcelera (Best, the Netherlands) offline.
Statistical analysis
Data are presented as median (inter-quartile range
[IQR]), percentages or absolute values. For not normally
distributed variables we used non-parametric test exclu-
sively. For correlation between two variables, Spearman’s
rank correlation was used and for differences between
two groups we used Mann-Whitney’s U-test. Categorical
data were analyzed with Fisher’s exact test. HsTNT and
BNP were log transformed with natural logarithm due to
skewed distribution. Receiver operating characteristics
(ROC) were used to define optimal cut-off values using
the maximal area under the curve (AUC). Our aim was
to investigate how 1-year mortality can be predicted by
more than one explanatory variable measured early dur-
ing ICU stay. Since we did not have any censored data
during this period and odds ratio was the outcome of
hsTNT
Figure 1 Receiver operating characteristic (ROC) for hsTNT
and E/é. With regards to 1-year mortality the area under the
curve (AUC) for high-sensitive Troponin T (hsTNT) was 0.76 (95% CI
0.612- 0.907, p = 0.004) and for E/é 0.703 (95% CI 0.535- 0.871,
p = 0.023).
Bergenzaun et al. BMC Anesthesiology 2012, 12:25 Page 3 of 8
http://www.biomedcentral.com/1471-2253/12/25interest, logistic regression was chosen to be the most
suitable method [38,39]. Multivariate (backward stepwise
selection method with probability for the removal of
0.10) logistic regression analyses were used to determine
the association of variables with 1-year mortality. Factors
predictive of 1-year survival in univariate analyses were
hsTNT, APACHE II, SOFA, E/é and age. As APACHE II
score, but not SOFA score, is a validated general risk-
prognostication system we used it in our logistic regres-
sion [40]. Additionally we performed a multivariate
logistic regression with creatinine, as a marker of renal
dysfunction, and pre-existing cardiac disease including
atrial fibrillation. Odds ratios (OR) were calculated. The
relationship between hsTNT quartiles and mortality was
investigated by logistic regression. The intra- and inter-
observer variability of echocardiographic parameters was
measured by the CV. CV was defined as the ratio of the
standard deviation to the mean multiplied by 100. All
probability values are two-tailed and significance was set
at p < 0.05. The analyses were performed using SPSS
18.0 (SPSS, Chicago, IL, U.S.).
Results
The original study included 55 consecutive patients.
Two patients were excluded due to lack of written con-
sent. One patient died 4 h after study inclusion and be-
fore echocardiographic examination, one patient was too
obese to allow TTE and one patient was incorrectly
registered in the echocardiography database. One patient
moved abroad after 6 months, which precluded longer-
term follow-up. These six patients were excluded from
statistical analysis, resulting in a total of 49 analysed
patients. Two-thirds of the population suffered from
septic shock. The remaining patients suffered from
shock due to other causes (pancreatitis, post-major non-
cardiac surgery, intoxication and multiorgan failure,
gastrointestinal bleeding and portal hypertension or
unknown cause). Pre-existing cardiac disease was pres-
ent in 24% of patients, defined as severe arrhythmia,
heart failure or ischemic heart disease. Norepinephrine
was used as a vasopressor. Twelve patients received
dobutamine and one adrenaline at inclusion. Ten
patients received levosimendan during the study
period. In all, 49% had pre-existing treatment with β-
blockers, ACE-inhibitors, Ca-channel blockers, and/or
nitrates.
Biochemical cardiac markers
HsTNT was detectable in all 49 patients, ranged from
<5 to 2592 ng/l (median 80 ng/l [IQR 24.0-193.5]) and
was elevated (>14 ng/l) in 45 (92%) patients. With regard
to 1-year mortality, AUC for hsTNT was 0.76 (95% CI
0.612- 0.907, p = 0.004), with 72% sensitivity and 82%
specificity for a cut-off value of 117.5 ng/l (Figure 1).BNP ranged from 29 to 2031 pmol/l (median189 pmol/l
[IQR 107–375]) (Table 1) and was elevated (>30 pmol/l)
in 48 (98%) patients. AUC for BNP was 0.603 (95% CI
0.415 to 0.791, p = 0.26). hsTNT correlated with critical
illness scores APACHE II [r = 0.335, p = 0.019] and SOFA
[r = 0.301, p = 0.036]. There was no significant associ-
ation with BNP, age, gender, diabetes, previous cardiac
disease, E/é, lactate levels or creatinine.
Echocardiography
A total of 46 echocardiographic examinations were avail-
able for analysis, since 3 examinations were lost during
the installation of a new offline storage and analysis sys-
tem. The intra- and interobserver variability for echocar-
diographic parameters of LV systolic function ranged
from 3.1% to 9.9% as reported earlier [35] and for echo-
cardiographic parameters of LV diastolic function from
3.2% to 9.6%. There were no significant differences be-
tween survivors and non-survivors in any of the mea-
sured LV systolic function parameters (Table 2). The LV
diastolic function parameters, E/é and La volume, surro-
gates of LV filling pressure, differed significantly between
survivors and non-survivors (E/é median 9.9 vs 11.7,
p = 0.023; La volume median 24 ml/m2 vs 31 ml/m2,
p = 0.024) respectively (Table 2). In this study La volume
was only feasible in 38 patients. Further, as La volume
was less significant than E/é, E/é was chosen for further
calculations. E/é correlated with age (r = 0.474, p=0.001).
Table 1 Patient characteristics
Variable n = 49
Demographics
Median age, y 65 (54–74)
Female sex 14 (29%)
Previous medical history
Diabetes mellitus 6 (12%)
Hypertension 12 (24%)
Cardiac disease 12 (24%)
Pre- existing therapy 24 (49%)
Clinical data
APACHE II 24 (19–29)
SOFA score 11 (9–13)
Mechanical ventilation,% 90
Biochemical markers
Creatinine, μmol/l 155 (92.0-231.0)
Lactate, mmol/l 2.3 (1.6-3.3)
hsTNT, ng/l 80 (24.0-193.5)
BNP, pmol/l 189 (107–375)
Echocardiographic data n = 46
LVEF,% 45 (40–55)
La volume, ml/m2 24 (21.0-31.6)
AVPDm, mm 10.7 (8.0-12.7)
E, cm/s 89 (71–104)
A, cm/s 67 (52–91)
E/A 1.3 (0.9-1.5)
DT, ms 165 (148–200)
TDIs, cm/s 8.6 (7.1-10.0)
é, cm/s 8.4 (7.1-10.0)
á, cm/s 9 (7.5- 12.3)
E/é 10.1 (8.5-12.2)
LVOT VTI, cm 17 (15–23)
Mortality
7 day mortality,% 16
28 day mortality,% 27
1 year mortality,% 37
ICU mortality,% 27
Data are presented as median (lower quartile- upper quartile) or in numbers
(%). APACHE II=Acute Physiology and Chronic Health Evaluation;
SOFA=Sequential Organ Failure Assessment.
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hsTNT, APACHE II, SOFA, lactate, BNP, La volume, gen-
der, diabetes or previous cardiac disease. E/é was under 8
in 18%, between 8 and 15 in 71% and over 15 in 11% of
patients. With regards to 1-year mortality, AUC for E/é
was 0.703 (95% CI 0.535- 0.871, p=0.023) with 72% sen-
sitivity and 65% specificity for a cut-off value of 10.1
(Figure 1). The other LV diastolic function parameters did
not differ significantly between survivors and non-survivors
(Table 2).Predictors of 1 year-mortality
Univariate analysis showed that hsTNT levels were sig-
nificantly higher in non-survivors (median 168 [IQR
89.8-358] ng/l) than in survivors (median 60 [IQR 17–
99.5] ng/l), p =0.003 while BNP was not significantly dif-
ferent (p = 0.26). Other predictors identified by univariate
analysis were APACHE II, SOFA, age and the LV dia-
stolic function parameters E/é and La volume (Table 2).
Out of 45 patients with TNT values > 14 ng/l (99th
percentile), 18 (40%) were non-survivors and 27 (60%)
were survivors. The remaining four patients with
hsTNT ≤ 14 ng/l were all survivors.
A multivariable logistic regression analysis including
hsTNT, APACHE II, E/é and age, identified hsTNT
(p = 0.010) as the only independent predictor of 1-year
mortality with an adjusted OR of 2.0 (95% CI 1.2- 3.5).
Logistic regression showed increasing odds ratios for
mortality for increasing hsTNT quartiles (OR of 3.7
[95% CI 0.3- 41.6], p = 0.294; OR of 9.4 [95% CI 0.93-
95.9], p = 0.058; OR of 22 [95% CI 2.1- 236.1], p = 0.011).
When we included SOFA score to the model it became
unstable due to correlations between the explanatory
variable SOFA score and APACHE. When including cre-
atinine and pre-existing cardiac disease (including atrial
fibrillation) as independent variables in the model this
did not affect the model or contribute with any
significance.
Discussion
The main findings of this study are: 1) hsTNT was the
only independent predictor of 1-year mortality after ad-
justment for other factors; 2) elevated levels of hsTNT
were found in the majority of patients; 3) E/é was higher
in non-survivors; 4) neither BNP nor echocardiographic
LV systolic function parameters were predictive of 1-year
mortality.
Early elevation of hsTNT is an independent predictor of
1-year mortality in critically ill patients with shock
Elevation of cTn is common among ICU patients for
several reasons including myocardial infarction, sepsis
and renal failure [41] and is known to be predictive of
mortality during shorter follow-up periods such as ICU-
and hospital mortality [14,15,41-44]. Even in critically ill
patients where coronary artery disease has been
excluded, elevated cTn is known to be associated with
increased mortality [16]. In medical ICU patients, ele-
vated cTn measured within 12 h of admission has been
shown to be an independent risk factor for 30-day and
2-year mortality after adjustment for severity of illness
[42]. The recent introduction of a new generation of
high sensitivity assays for cTn, with a lower detection
limit and sufficient analytical precision [9,10], allows the
detection of elevated cTn in a considerably higher







Median age, y 60 (49.5-68.5) 72 (68.3-76) 0.031
Female sex 10 (32%) 4 (22%) ns
Previous medical history
Diabetes mellitus 4 (13%) 2 (11%) ns
Hypertension 9 (29%) 3 (17%) ns
Cardiac disease 8 (26%) 4 (22%) ns
Pre-existing therapy 14 (45%) 10 (56%) ns
Clinical data
APACHE II 22 (16–26) 28.5 (21–34) 0.009
SOFA score 10 (9–13) 13 (11–14) 0.024
Mechanical ventilation 29 (94%) 15 (83%) ns
Biochemical markers
Creatinine, μmol/l 154 (88–221) 171 (105–238) ns
Lactate, mmol/l 2.2 (1.6-3.2) 2.5 (1.7-4.4) ns
hsTNT, ng/l 60 (17.0-99.5) 168 (89.8-358) 0.003
BNP, pmol/l 159 (84–339) 241 (149–446) 0.26
Echocardiographic data
Survivors (n = 28) Non- survivors (n =18)
LVEF,% 48 (40–55) 45 (36–65) 0.87
La volume, ml/m2 24 (20–27) 31 (25–36) 0.024
AVPD, mm 11.5 (8.8- 13) 9.0 (7.5-11) 0.087
E, cm/s 83.5 (68.8-96.3) 102.5 (75.5-113.0) ns
A, cm/s 67.5 (57.0-92.3) 63.5 (40.0-86.0) ns
E/A 1.2 (0.85-1.4) 1.4 (1.0-1.9) ns
DT, ms 170 (150–200) 160 (135–195) ns
TDIs, cm/s 8.5 (7.2-9.7) 8.7 (6.7-10) ns
é, cm/s 8.4 (7.5-10.8) 7.9 (6.3-9.6) ns
á, cm/s 9.9 (7.7-12.3) 8.8 (7.5-10) ns
E/é 9.9 (8.1-10.9) 11.7 (9.8-14.8) 0.023
LVOT VTI, cm 20 (15–23) 17 (16–23) 0.18
Data are presented as median (lower quartile- upper quartile) or in numbers (%).
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patients with cardiovascular disease [10,11]. In general,
renal insufficiency and cardiologically ill populations, de-
tectable levels of hsTnT are associated with adverse out-
comes [13,45,46]. However in critically ill patients,
information about the value of high sensitive cTn is
scarce. In a study by Rosjö et al. [17], hsTNT on inclu-
sion was detectable in all patients with sepsis and septic
shock. Further, hsTNT correlated to severity of disease
and was significantly higher in hospital non-survivors
but could not be identified as an independent predictor
of mortality. Reynolds et al. [15] showed that an
increased cTnI concentration while in ICU was asso-
ciated with increased mortality in hospital, after adjust-
ing for admission characteristics, age, severity of illnessat admission, organ support, and serum creatinine con-
centrations. These results are in line with our study,
where hsTNT measured within 12 h was detectable in
100%, elevated in 92% of patients, and correlated signifi-
cantly with critical illness scores. Further, hsTNT was
identified as the only independent predictor of even
longer-term (1-year) mortality. The findings are
strengthened by the increased odds ratios for mortality
for increasing quartiles of hsTNT identified in this
population although the wide CIs indicate that larger
studies are needed to support our findings.
We also note that median hsTnT in non-survivors was
higher in our study compared to the study by Rosjö
et al.: 168 vs 54 ng/l. As the frequency of cardiovascular
disease was comparable in both studies (24% and 26%
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sicker patients in our non-survivor group (median SOFA
13 vs 9 in Rosjö et al.). Since this was an exploratory
study, and due to the paucity of literature regarding
accepted levels of hsTNT in the critically ill, we chose
the cut-off level with the best balance of specificity and
sensitivity. We do not know if this is adequate and we
hope that future studies will inform us as to what to ex-
pect from different critically ill populations. We note
that the cut-off point identified by our ROC analysis is
much higher than that identified in non-critically ill
patients. The reason for this and its relevance is unclear
and deserves attention in future studies.
We investigated if there was a confounding relation-
ship between hsTNT and pre-existing cardiac disease or
renal insufficiency but found no significant association
which is propably due to sample size. Additionally when
entering these confounders into the multivariable model,
hsTNT could still be identified as the sole significant
predictor of mortality.
Diastolic but not systolic function parameters are
associated with mortality
Impairment of myocardial function in patients with
shock is often masked by concurrent elevations in car-
diac index and a low systemic vascular resistance, mak-
ing parameters such as LVEF often unreliable for
monitoring LV systolic function and as a prognostic
marker [1,47]. Additionally, markers of LV systolic func-
tion are frequently described to be normal or near nor-
mal [3,4,24] in these patients. This is in line with our
results, where all echocardiographic parameters of LV
systolic function were normal or mildly reduced and
none were predictive of 1-year mortality. LV diastolic
dysfunction with increased filling pressures is known to
be predictive of mortality in cardiac patients [30] but has
shown conflicting results regarding prognosis in ICU
patients [3,4,24,25]. In our study E/é and La volume,
both surrogates of LV filling pressure, were predictive of
mortality but other diastolic parameters were not. E/é
did, as expected, correlate significantly with age but not
with hsTNT, BNP, APACHE II, SOFA score or lactate.
These results were to some extent unexpected, as E/é
has been shown in previous studies to be correlated to
the severity of critical illness (3, 47).
Recent studies allude to the importance of E/é to
prognosis in critically ill patients with shock [3,25]. Stur-
gess et al. [25] identified E/é as an independent predictor
of hospital mortality, although with a considerably
higher cut-off value than in our study (E/é = 14.5). This
might be attributable to a higher percentage of pre-
existing cardiac disease (43% in that study vs 24% in our
study) and narrower inclusion criteria (septic shock vs
shock). An É/é ratio < 8 cm/s is usually associated withnormal filling pressure and E/é ratio > 15 cm/s com-
monly with increased filling pressure [30]. In our study
median E/é was 10.1, thus representing a level between
8–15 where filling pressures might be elevated according
to international guidelines [30]. Our study population
represents a group of patients with increased age, pre-
existing cardiovascular disease as well as acute critical
illness. All can affect diastolic function and thus filling
pressures. As we do not know to what extent E/é is
affected by either of these different entities, we cannot
separate their cardiac effects. Although E/é was only
mildly increased it was still predictive irrespective of the
underlying cause.
BNP is not a valuable marker of 1-year mortality in this
population
The role of natriuretic peptides as prognostic markers is
well described in patients with cardiovascular disease
[18]. Even in ICU patients several outcome studies refer
to their usefulness [21,22]. Nevertheless the prognostic
value of natriuretic peptides has been described as ques-
tionable [4], as they can be elevated due to a variety of
reasons in critically ill patients [20]. Age, gender, pre-
existing or critical illness associated renal and myocar-
dial impairment as well as inflammatory states such as
sepsis or septic shock all affect BNP [20,22]. In our
study, elevated BNP was seen in most patients (98%) but
did not correlate with critical illness (APACHE II) or
organ dysfunction (SOFA), nor discriminated survivors
from non-survivors. As LV systolic function overall was
near normal and no patient had acute heart failure
as the sole diagnosis, we speculate that elevated BNP
due to other factors than heart failure is of little prog-
nostic value.
Limitations
Our study group containing the sickest of ICU patients
with hemodynamic instability, implying cardiovascular
impairment, is prone to bias and our results could have
been completely different in another set of ICU patients.
Therefore there is a risk of bias that could have led to
overestimation of the prognostic ability of hsTNT. We
have not excluded patients with known heart failure or
atrial fibrillation, nor have we excluded patients with
new onset of atrial fibrillation during their critical illness,
which might have influenced our results. We did not
record the absence or presence of ischemic ECG
changes. This could have been of additional value to the
echocardiographic examination in interpreting the likely
cause of hsTNT elevations although this was not the
aim of this study. In this observational study our
intention was to investigate a group of critically ill
patients with shock knowing that increased age, the like-
lihood of pre-existing cardiovascular disease and critical
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lation, ischemic and/or cardiomyopathy probably would
influence our results. Excluding patients with pre-
existing cardiac disease would probably have reduced
the cardiological impact of the regression model but
would also have made the sample less representative of
the population of critically ill patients. Since coronary
angiography was not a possibility in this study, and since
patients did not have pre-morbid echocardiograms, it is
possible that we may have identified a subpopulation of
critically ill patients with cardiac disease. We maintain
however, that in this general group of very ill patients
with shock, only hsTNT was indentified as a predictor
of 1-year mortality, regardless of aetiology and back-
ground co-morbidity. A larger study stratifying BNP by
age and gender might have yielded different results. TDI
measurements were only done at the septal mitral annu-
lus whereas current recommendations include both the
septum and lateral wall [30]. Further a blinded assess-
ment of echocardiographic data would have been desir-
able. Finally, the sample size is small; hence only limited
variables could be used for the model, increasing the
likelihood of confounding. We have attempted to reduce
this by using univariate analysis to identify probable pre-
dictors, limiting the number of predictors and including
these in the multivariate model. The results were
congruent for different models that showed some
consistency over the outcome predictor.
The strength of this study is that both LV systolic and
diastolic echocardiographic measurements together with
cardiac biomarkers were analysed as predictors of
longer-term outcome.
Conclusion
In this observational, cohort study, we found that
hsTNT seems to be important for prognosis in the crit-
ically ill. Although in our study early measurement of
hsTNT correlated with critical illness scores and was
identified as the only independent predictor of 1-year
mortality, clinicians should be aware that studies as ours
are explorative and the results should be interpreted
cautiously. Future studies should inform us on the re-
producibility of these results, what levels to expect in
different critical care subpopulations, what decision lim-
its to implement and their clinical significance.
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